Prot # AI444052: A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C

Project: Research project

Project Details

StatusFinished
Effective start/end date5/9/125/9/15

Funding

  • Bristol-Myers Squibb Company (Prot # AI444052)